What's Happening With Cancer Biotech Erasca Shares This Thursday?

Erasca Inc. Stock Experiences Volatility Amid Acquisition Rumors

Erasca Inc. (NASDAQ: ERAS) saw its share price surge by nearly 60% to $6.12 on Wednesday, before retreating to a low of $4.33 on Thursday.

• Erasca shares have been on the rise.

This sharp movement followed speculation about a potential acquisition, with reports suggesting that AbbVie Inc. (NYSE: ABBV) was in advanced negotiations to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD).

Shortly after these reports surfaced, AbbVie informed Reuters that it was “not in discussions with Revolution Medicines.”

Revolution Medicines is a late-stage biotechnology company specializing in innovative targeted treatments for cancers driven by RAS mutations.

Their research and development pipeline features RAS(ON) inhibitors, which are designed to block a variety of cancer-causing RAS protein variants.

In September 2025, Revolution Medicines released updates from its Phase 1 Daraxonrasib trials, including results for patients with RAS-mutant pancreatic cancer.

Erasca, also a clinical-stage biotech firm, is dedicated to the discovery, development, and commercialization of therapies targeting cancers driven by the RAS/MAPK pathway.

The company is currently running two Phase 1 clinical trials for its lead candidate, ERAS-0015, in patients with RAS-mutant solid tumors. Initial results are anticipated in 2026.

The Wall Street Journal also noted that acquiring Revolution Medicines could significantly strengthen AbbVie’s position in the global cancer drug market, which exceeds $250 billion annually.

Latest Stock Performance

• Erasca (ERAS) shares are up 0.87% at $5.23.
• Revolution Medicines (RVMD) shares are down 5.65% at $96.91 as of Thursday’s publication.

Image credit: Shutterstock

Stock Snapshot

• Erasca Inc (ERAS): $5.24 (+1.26%)
• AbbVie Inc (ABBV): $224.35 (-3.88%)
• Revolution Medicines Inc (RVMD): $96.95 (-5.60%)